OncoMatch/Clinical Trials/NCT06030440
De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
Is NCT06030440 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies non-drug interventions for squamous cell carcinoma of the oral cavity.
This randomized, prospective, multicenter phase II/III trial will study the reduction of radiation volume by eliminating radiotherapy (RT) to the elective neck using strictly defined surgical and radio-oncological standards to reduce radiotherapy-related long-term side effects without affecting locoregional control.
Check if I qualifyExtracted eligibility criteria
Disease stage
Excluded: Stage PT1/2PN0
except glottis cancer (pT1/2pN0)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: surgery — primary tumor and neck dissection
Surgery of primary tumor and neck dissection performed according to predefined surgical standard
Cannot have received: radiotherapy
prior radiotherapy in the head and neck region
Cannot have received: chemotherapy
prior chemo- or immunotherapy (neoadjuvant/induction)
Cannot have received: immunotherapy
prior chemo- or immunotherapy (neoadjuvant/induction)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06030440 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiotherapy, chemotherapy, immunotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify